NeuroOne Medical Technologies Corporation Common Stock
NMTC
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.71 – $0.80
Volume21,741
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.83M
Price / earnings
—
Price / book
1.81×
Price / sales
0.55×
EV / sales
0.38×
EV / EBITDA
-0.62×
Profitability
Earnings per share
-$0.82
Return on assets
-120.36%
Return on equity
-197.62%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.84×
Quick ratio
1.71×
Cash ratio
1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.16M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NMTC, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$1.97M
$1.86M
$2.89M
$5.74M
$1.7M
$1.39M
$3.27M
$272.28K
Cost of revenue
$790.5K
$871.79K
$1.32M
$1.21M
$781.22K
$615.49K
$1.35M
$131.22K
Gross profit
$1.18M
$990.26K
$1.57M
$4.53M
$914.84K
$771.06K
$1.93M
$141.06K
Selling, general and administrative
$2.18M
$1.92M
$1.89M
$1.78M
$1.62M
$1.94M
$2.04M
$1.84M
Research and development
$1.43M
$1.47M
$1.39M
$1.12M
$1.18M
$1.51M
$1.17M
$1.11M
Total operating expenses
$3.61M
$3.39M
$3.28M
$5.9M
$2.8M
$3.45M
$215.68K
$2.96M
Operating income
-$2.42M
-$2.4M
-$1.71M
-$1.37M
-$1.89M
-$2.68M
$1.71M
-$2.82M
Interest expense
$0
$0
$0
-$334.06K
-$9.33K
$0
-$324.74K
-$228.99K
Income before taxes
-$2.01M
-$2.38M
-$1.44M
-$1.62M
-$1.5M
-$2.27M
$1.79M
-$3.35M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.01M
-$2.38M
-$1.44M
-$1.62M
-$1.5M
-$2.27M
$1.79M
-$3.35M
Net income attributable to common shareholders
-$2.01M
-$2.38M
-$1.44M
-$1.62M
-$1.5M
-$2.27M
$1.79M
-$3.35M
EBITDA
-$2.38M
-$2.34M
-$1.64M
-$1.31M
-$1.82M
-$2.61M
$1.78M
-$2.75M
Basic earnings per share
-$0.23
-$0.28
-$0.18
-$0.19
-$0.19
-$0.44
$0.36
-$0.67
Diluted earnings per share
-$0.28
-$0.28
-$0.18
-$0.19
-$0.19
-$0.44
$0.36
-$0.67
Recent news
Company coverage with links to the original publishers.
NeuroOne Medical Technologies reported strong Q3 2025 performance with 105% product revenue growth, improved gross margins, and promising clinical milestones for its OneRF ablation system, including the first patient achieving 12-month seizure freedom.
NeuroOne Medical Technologies Corporation will release its fiscal first quarter 2025 financial results on February 12, 2025, and host an investor conference call to discuss the results and provide a corporate update.
NeuroOne Medical Technologies Corporation has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, and faces delisting if it fails to regain compliance within the grace period.
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.